← boardnext 2026-11
CRDF
Cardiff Oncologydistress 3/10 · well-funded / low risk$0.860%today-81% from 52w high
Lead: first-line RAS-mutated metastatic colorectal cancer · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$46M
Runway
1.2 yrs
Shares 1y
+3%
Price & events
-71.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-1.6%
1W
-31.5%
1M
-48.7%
3M
-70.5%
6M
-80.0%
1Y
-64.8%
2Y
-83.9%
5Y
-95.1%
All
Overview
- Market Cap
- $58.52M
- Volume
- 28.61K
- 52 Week Range
- $0.84 – $4.45
- Total Shares
- 68.37M
- Float Shares
- 65.93M
- Short %
- 19.19%
- % Held by Insiders
- 5.91%
- % Held by Institutions
- 32.87%
- RVOL
- 0.02x
- Beta
- 1.44
Pipeline stages · 1 programs
Onvansertib, FOLFIRI, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | Onvansertib, FOLFIRI, Bevacizumab | Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation | — | active not recruiting |
Catalyst news & presentations · 4
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- H1 2026regulatory submissionFiled (NDA/BLA)Onvansertib · FDA meeting to review registrational programSEC 8-K
- June 3, 2026readoutPhase 2onvansertib · Interim results from randomized Phase 2 CRDF-004 trial.SEC 8-K
- July 29, 2025 at 4:30 p.m. ETreadoutPhase 2onvansertib · Positive data from ongoing CRDF-004 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $5 (+509% upside) · 7 analysts
- 2026-06-03Craig-HallumBuy → Hold
- 2026-06-01TD CowenBuy → Hold
- 2026-06-01HC Wainwright & Co.Buy → Neutral
- 2026-02-25Piper SandlerOverweight
- 2026-01-28HC Wainwright & Co.Buy
- 2025-08-06HC Wainwright & Co.Buy
Competitors — first-line RAS-mutated metastatic colorectal cancer
- none identified
Recent news
- 2026-07-17Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
- 2026-07-16Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
- 2026-07-16Form 4 Cardiff Oncology Inc For: 16 July By Investing.com - Investing.com Nigeria
- 2026-07-16Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock - Investing.com
- 2026-07-16Insider Purchase: Director at $CRDF Buys 687,285 Shares - Quiver Quantitative
- 2026-07-16Cardiff Oncology Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing - marketscreener.com
- 2026-07-16Cardiff Oncology (CRDF) director buys 687,285 shares and warrants - Stock Titan
- 2026-07-16Cardiff Oncology (CRDF) CEO adds common shares and new warrants stake - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.